Durable Trial Results Might Change The Case For Recursion Pharmaceuticals Stock
- Recursion Pharmaceuticals reported new Phase 2 results for REC-4881 in familial adenomatous polyposis, showing broad reductions in upper and lower gastrointestinal polyp burden with a generally well tolerated safety profile and plans to move toward a registrational trial after ongoing FDA discussions.
- The durability of polyp burden reductions after REC-4881 treatment and the focus on higher risk larger polyps highlight a potential path for Recursion Pharmaceuticals to translate its AI driven discovery work into a more clinically differentiated asset.
- This article examines how Recursion Pharmaceuticals' investment narrative may change as REC-4881's durable FAP results further define the clinical pipeline.
Recursion Pharmaceuticals Investment Narrative Recap
To own Recursion Pharmaceuticals, you need to buy into the analyst consensus Narrative on Simply Wall St that an AI native discovery engine can eventually turn today’s pipeline and partnerships into meaningful products while the business is still loss making. The latest quarter showed US$18.6 million in revenue and a net loss of US$119.0 million, so the operating model is still firmly investment heavy.
The nearer term catalyst now sits with execution on REC 4881 and other clinical programs, while keeping operating expenses aligned with recent guidance and the extended cash runway. The biggest current risk is that clinical timelines, partnership milestones or future fundraising do not line up cleanly with that cash use, which could prolong heavy losses.
The earnings release on November 2, 2026 is the clearest operational lens on that risk reward trade off. Recursion Pharmaceuticals lifted quarterly revenue to US$18.55 million compared with US$5.18 million a year ago, while the quarterly net loss narrowed from US$162.25 million to US$119.04 million and loss per share improved from US$0.36 to US$0.22.
Across the first nine months, revenue of US$32.69 million and a loss of US$367.55 million, or US$0.69 per share, underline how dependent the company still is on external funding and partnership receipts. For anyone watching REC 4881’s progress, the key question is whether upcoming data and potential milestones arrive in time to support that burn profile without excessive additional dilution.
Recursion Pharmaceuticals' narrative projects US$116.3 million in revenue and US$20.7 million in earnings by 2029. This assumes 28.5% yearly revenue growth and an earnings swing of about US$539.6 million from current earnings of a US$518.9 million loss to the forecast profit.
Uncover why Recursion Pharmaceuticals' fair value indicates a 120% potential upside to its current price that could narrow quickly.
Exploring Other Perspectives
Some of the most optimistic analysts framed the REC 4881 story very differently to the consensus before this news. You can see that in their assumptions for roughly US$382.1 million of revenue and US$65.7 million of earnings by 2029, compared with the base case of US$116.3 million and US$20.7 million. If you think Recursion Pharmaceuticals’ new FAP data or the appointment of Fred Hassan as Chair could shift how well the pipeline converts into those kinds of numbers, it is worth comparing both narratives and deciding which feels closer to your own expectations.
Explore 6 other Recursion Pharmaceuticals fair value estimates, including one that suggests up to 200% upside from the current price.
Decide For Yourself
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- See our latest analysis for Recursion Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.
Looking for more investment ideas beyond Recursion Pharmaceuticals?
Once you have formed a view on Recursion Pharmaceuticals and REC 4881, it can help to compare that perspective with other opportunities so your portfolio is not leaning on a single story.
- If you want potential upside with strict quality filters, scan through 20 high quality undiscovered gems that already show strong fundamentals but still fly under most radars.
- For readers who care more about resilience than excitement, compare Recursion Pharmaceuticals with 29 resilient stocks with low risk scores that score well on stability and downside protection.
- If your priority is balance sheet strength to support long development cycles, broaden your watchlist using the list of solid balance sheet and fundamentals (23 results) and see which businesses pair financial flexibility with long term projects.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com